Royalty Pharma’s milestone payment to Arrowhead; Abeona’s $75M offering

Plus, news about Soleno, No­vo Nordisk and Car­dior Phar­ma­ceu­ti­cals:

Roy­al­ty Phar­ma pays Ar­row­head Phar­ma­ceu­ti­cals: The $50 mil­lion mile­stone pay­ment comes af­ter the com­plet­ed en­roll­ment of a Phase 3 tri­al in­ves­ti­gat­ing ol­pasir­an in pa­tients with ath­er­o­scle­rot­ic car­dio­vas­cu­lar dis­ease and el­e­vat­ed lipopro­tein. Ar­row­head could still get an­oth­er $485 mil­lion in mile­stone pay­ments for the drug. — Kather­ine Lewin

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.